Literature DB >> 9564823

Leukemia inhibitory factor modulates interleukin-1beta-induced activation of the hypothalamo-pituitary-adrenal axis.

C J Auernhammer1, V Chesnokova, S Melmed.   

Abstract

We have shown that leukemia inhibitory factor (LIF) is expressed in corticotroph cells and stimulates POMC gene expression and ACTH secretion in vivo and in vitro. We therefore examined the regulation of in vitro and in vivo pituitary LIF expression by cytokines known to stimulate the hypothalamo-pituitary-adrenal axis. In the corticotroph cell line AtT-20/D16v-F2, recombinant murine interleukin-1beta (IL-1beta; 0.1-10.0 ng/ml) caused a 5- to 10-fold increase in LIF messenger RNA (mRNA) levels. LIF mRNA expression was induced as early as 1 h, peaked at 2 h, and still persistently elevated above the baseline after 8 h. This effect of IL-1beta on LIF mRNA expression was abolished by preincubation with human IL-1 receptor antagonist (100 ng/ml) or antimurine IL-1beta antibody (10 microg/ml). Tumor necrosis factor-alpha (20 ng/ml) only modestly increased LIF mRNA, but was synergistic with IL-1beta (up to 2.5-fold). In contrast, IL-2 and IL-6 did not alter LIF mRNA. In C57BL/6 mice, i.p. injection of 100 ng IL-1beta increased plasma ACTH and corticosterone levels after 1 h (P < 0.02). In addition, pituitary LIF mRNA content was increased for up to 2 h in response to IL-1beta. In comparison to wild-type (+/+) B6D2F1 mice, LIF knockout mice with a deleted LIF gene (-/-) exhibited decreased plasma ACTH (631 +/- 61 vs. 376 +/- 50 pg/ml; P < 0.01) and corticosterone (783 +/- 85 vs. 433 +/- 51 ng/ml; P < 0.01) levels 1 h after i.p. IL-1beta administration. In conclusion, corticotroph LIF mRNA expression is specifically stimulated by IL-1beta and tumor necrosis factor-alpha. The attenuated hypothalamo-pituitary-adrenal response to IL-1beta in LIF knockout mice indicates that the effect of IL-1beta on ACTH secretion is modulated by LIF. Thus, LIF appears to function as an immune-neuroendocrine modulator signaling the hypothalamo-pituitary-adrenal axis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9564823     DOI: 10.1210/endo.139.5.6017

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  12 in total

Review 1.  The central role of SOCS-3 in integrating the neuro-immunoendocrine interface.

Authors:  C J Auernhammer; S Melmed
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

2.  Tbx19, a tissue-selective regulator of POMC gene expression.

Authors:  J Liu; C Lin; A Gleiberman; K A Ohgi; T Herman; H P Huang; M J Tsai; M G Rosenfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

3.  Developmental exposure to corticosterone: behavioral changes and differential effects on leukemia inhibitory factor (LIF) and corticotropin-releasing hormone (CRH) gene expression in the mouse.

Authors:  Robert N Pechnick; Anastasia Kariagina; Evelyn Hartvig; Catherine J Bresee; Russell E Poland; Vera M Chesnokova
Journal:  Psychopharmacology (Berl)       Date:  2006-01-14       Impact factor: 4.530

4.  Effects of leukemia inhibitory receptor gene mutations on human hypothalamo-pituitary-adrenal function.

Authors:  Tulay Guran; Omer Guran; Cem Paketci; Osman Kipoglu; Irfan Firat; Serap Turan; Zeynep Atay; Belma Haliloglu; Abdullah Bereket
Journal:  Pituitary       Date:  2015-08       Impact factor: 4.107

5.  Autoregulation of pituitary corticotroph SOCS-3 expression: characterization of the murine SOCS-3 promoter.

Authors:  C J Auernhammer; C Bousquet; S Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

Review 6.  Genetic Approaches to Hypothalamic-Pituitary-Adrenal Axis Regulation.

Authors:  Melinda G Arnett; Lisa M Muglia; Gloria Laryea; Louis J Muglia
Journal:  Neuropsychopharmacology       Date:  2015-07-20       Impact factor: 7.853

Review 7.  The Molecular Basis and Therapeutic Potential of Leukemia Inhibitory Factor in Cancer Cachexia.

Authors:  Ruijiang Zeng; Chang Tong; Xiangyang Xiong
Journal:  Cancers (Basel)       Date:  2022-06-15       Impact factor: 6.575

8.  Neuroprotective effect of leukemia inhibitory factor on antimycin A-induced oxidative injury in differentiated PC12 cells.

Authors:  Yangguang Han; Jing Xu; Zhigui Li; Zhuo Yang
Journal:  J Mol Neurosci       Date:  2013-05-01       Impact factor: 3.444

9.  Expression of leukemia inhibitory factor in craniopharyngioma.

Authors:  A Tran; K Kovacs; L Stefaneanu; G Kontogeorgos; B W Scheithauer; S Melmed
Journal:  Endocr Pathol       Date:  1999-06       Impact factor: 3.943

10.  The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway.

Authors:  Jong-In Park; Christopher J Strock; Douglas W Ball; Barry D Nelkin
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.